Rituximab may have been responsible for the tumor suppressive effect by not only the well‐known complement‐dependent cytotoxicity (CDC) and antibody‐dependent cell‐mediated cytotoxicity but also by PI3K‐mTOR axis suppression. Here, MTOR is linked to neoplasm.